-DOCSTART- -X- O
OBJECTIVE -X- _ O
: -X- _ O
This -X- _ O
study -X- _ O
reports -X- _ O
the -X- _ O
clinical -X- _ B-Outcome
characteristics -X- _ I-Outcome
and -X- _ I-Outcome
outcome -X- _ I-Outcome
of -X- _ O
HIV-associated -X- _ B-Intervention
Penicilliummarneffei -X- _ I-Intervention
infection -X- _ I-Intervention
in -X- _ O
northern -X- _ O
Vietnam. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
conducted -X- _ O
a -X- _ O
retrospective -X- _ O
chart -X- _ O
review -X- _ O
of -X- _ O
all -X- _ O
patients -X- _ O
with -X- _ O
laboratory -X- _ O
confirmed -X- _ O
Penicilliummarneffei -X- _ B-Intervention
infection -X- _ I-Intervention
admitted -X- _ O
to -X- _ O
the -X- _ O
National -X- _ O
Hospital -X- _ O
for -X- _ O
Tropical -X- _ O
Diseases -X- _ O
in -X- _ O
Hanoi -X- _ O
, -X- _ O
Vietnam -X- _ O
, -X- _ O
between -X- _ O
July -X- _ O
2006 -X- _ O
and -X- _ O
September -X- _ O
2009. -X- _ O
RESULTS -X- _ O
: -X- _ O
127 -X- _ O
patients -X- _ O
with -X- _ O
P. -X- _ B-Intervention
marneffei -X- _ I-Intervention
infection -X- _ I-Intervention
were -X- _ O
identified. -X- _ O
All -X- _ O
were -X- _ O
HIV-infected -X- _ O
; -X- _ O
median -X- _ O
CD4+ -X- _ O
T-cell -X- _ O
count -X- _ O
was -X- _ O
24 -X- _ O
cells -X- _ O
/ -X- _ O
Î¼l -X- _ O
( -X- _ O
IQR:12-48 -X- _ O
) -X- _ O
; -X- _ O
76 -X- _ O
% -X- _ O
were -X- _ O
men. -X- _ O
Common -X- _ O
clinical -X- _ O
features -X- _ O
were -X- _ O
fever -X- _ B-Outcome
( -X- _ I-Outcome
92.9 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
skin -X- _ I-Outcome
lesions -X- _ I-Outcome
( -X- _ I-Outcome
82.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
hepatomegaly -X- _ I-Outcome
( -X- _ I-Outcome
61.4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
lymphadenopathy -X- _ I-Outcome
( -X- _ I-Outcome
40.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
( -X- _ I-Outcome
59.1 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
cough -X- _ I-Outcome
( -X- _ I-Outcome
49.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Concurrent -X- _ I-Outcome
opportunistic -X- _ I-Outcome
infections -X- _ I-Outcome
were -X- _ I-Outcome
present -X- _ I-Outcome
in -X- _ I-Outcome
22.0 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
half -X- _ I-Outcome
of -X- _ I-Outcome
those -X- _ I-Outcome
had -X- _ I-Outcome
tuberculosis. -X- _ I-Outcome
Initial -X- _ I-Outcome
treatment -X- _ I-Outcome
regimens -X- _ I-Outcome
were -X- _ I-Outcome
: -X- _ I-Outcome
itraconazole -X- _ I-Outcome
or -X- _ I-Outcome
ketoconazole -X- _ I-Outcome
capsule -X- _ I-Outcome
( -X- _ I-Outcome
77.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
amphotericin -X- _ I-Outcome
B -X- _ I-Outcome
( -X- _ I-Outcome
20.5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
fluconazole -X- _ I-Outcome
( -X- _ I-Outcome
1.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
In-hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
was -X- _ I-Outcome
12.6 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
showed -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
difference -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
itraconazole -X- _ I-Outcome
( -X- _ I-Outcome
or -X- _ I-Outcome
ketoconazole -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
amphotericin -X- _ I-Outcome
B -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.43 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Dyspnea -X- _ I-Outcome
, -X- _ I-Outcome
ascites -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
LDH -X- _ I-Outcome
level -X- _ I-Outcome
were -X- _ I-Outcome
independent -X- _ I-Outcome
predictors -X- _ I-Outcome
of -X- _ I-Outcome
mortality. -X- _ I-Outcome
No -X- _ O
seasonality -X- _ O
was -X- _ O
observed. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
The -X- _ O
clinical -X- _ O
features -X- _ O
, -X- _ O
treatments -X- _ O
and -X- _ O
outcomes -X- _ O
of -X- _ O
HIV-associated -X- _ B-Patient
P. -X- _ B-Intervention
marneffei -X- _ I-Intervention
infection -X- _ I-Intervention
in -X- _ O
northern -X- _ O
Vietnam -X- _ O
are -X- _ O
similar -X- _ O
to -X- _ O
those -X- _ O
reported -X- _ O
in -X- _ O
other -X- _ O
endemic -X- _ O
regions. -X- _ O
Dyspnea -X- _ B-Outcome
was -X- _ I-Outcome
an -X- _ I-Outcome
important -X- _ I-Outcome
predictor -X- _ I-Outcome
of -X- _ I-Outcome
mortality. -X- _ I-Outcome
More -X- _ I-Outcome
patients -X- _ I-Outcome
were -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
itraconazole -X- _ I-Outcome
than -X- _ I-Outcome
amphotericin -X- _ I-Outcome
B -X- _ I-Outcome
and -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
difference -X- _ I-Outcome
in -X- _ I-Outcome
treatment -X- _ I-Outcome
outcome -X- _ I-Outcome
was -X- _ I-Outcome
observed. -X- _ I-Outcome
It -X- _ O
would -X- _ O
be -X- _ O
of -X- _ O
clinical -X- _ O
value -X- _ O
to -X- _ O
compare -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
oral -X- _ O
itraconazole -X- _ O
and -X- _ O
amphotericin -X- _ O
B -X- _ O
in -X- _ O
a -X- _ O
clinical -X- _ O
trial -X- _ O
. -X- _ O

